We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Trial investigator Ali Taher said the findings demonstrate that Reblozyl sustained elevated hemoglobin levels in most patients “regardless of their baseline hemoglobin status.” Read More
Bristol Myers Squibb (BMS) is evaluating its CAR-T therapy Breyanzi for use during earlier lines of therapy for adult lymphoma patients and said early treatment significantly improved patient outcomes in a late-stage trial. Read More
Byondis, a Dutch biopharma company focused on oncology drugs, reported that its late-stage trial evaluating its antibody-drug conjugate candidate in HER2-positive breast cancer met its primary endpoint, a development that’s given it confidence to file for FDA approval by the end of the year. Read More
The new results make Keytruda the first immunotherapy to show a benefit for treating kidney cancer in an adjuvant setting, said trial investigator Toni Choueiri. Read More
AstraZeneca’s (AZ) and Merck’s blockbuster cancer drug Lynparza (olaparib) has made a strong showing in a phase 3 trial evaluating it as an adjuvant treatment for an early form of breast cancer, according to early results from the study. Read More
The company did not disclose full results from the phase 3 trial in 86 children aged two to 17 years but said it will present the data at a conference this week. Read More
Novartis said its top-selling drug Cosentyx (secukinumab) significantly delayed time to worsening of symptoms in pediatric patients with juvenile psoriatic arthritis (JPsA) and enthesitis-related arthritis (ERA) in a late-stage study. Read More
The FDA has set a target action date of Nov. 30 and does not plan to hold an advisory committee meeting to discuss the NDA, the company said. Read More